Increasing numbers and complexity of Staphylococcus aureus bloodstream infection—14 years of prospective evaluation at a German tertiary care centre with multi-centre validation of findings

Mathé, Philipp; Göpel, Siri; Hornuss, Daniel; Tobys, David; Käding, Nadja; Eisenbeis, Simone; Kohlmorgen, Britta; Trauth, Janina; Gölz, Hanna; Walker, Sarah V.; Mischnik, Alexander; Peter, Silke; Hölzl, Florian; Rohde, Anna M.; Behnke, Michael; Fritzenwanker, Moritz; Häcker, Georg; Steffens, Benedict; Vehreschild, Maria; Kramme, Evelyn; Falgenhauer, Jane; Peyerl-Hoffmann, Gabriele; Seifert, Harald; Rupp, Jan; Gastmeier, Petra; Imirzalioglu, Can; Tacconelli, Evelina; Kern, Winfried; Rieg, Siegbert; Bader, Barisch; Blum, Yannic; Buhl, Michael; Cattaneo, Chiara; Dinkelacker, Ariane Gertraud; Gladstone, Beryl Primerose; Kleipaß, Matthias; Lenke, Dana; Olawumi-Hurter, Sara Christina; Diaz, Luis Alberto Peña; Pilarski, Georg; Proske, Susanna; Thoma, Norbert

doi:10.1016/j.cmi.2023.05.031

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15] Many studies indicate that the incidence of methicillinresistant Staphylococcus aureus (MRSA)-induced osteomyelitis is increasing yearly. [16,17] Vancomycin (Van), a glycopeptide antibiotic with antibacterial activity against staphylococci, streptococci, and other G + bacteria, is particularly effective against MRSA. [18] Hence, it is the best bactericidal agent for the treatment of G + bacterial infections.…”

Section: Introductionmentioning

confidence: 99%

Injectable Nano‐Micro Composites with Anti‐bacterial and Osteogenic Capabilities for Minimally Invasive Treatment of Osteomyelitis

Lu,

Zhao,

Wang

et al. 2024

Advanced Science

View full text Add to dashboard Cite

The effective management of osteomyelitis remains extremely challenging due to the difficulty associated with treating bone defects, the high probability of recurrence, the requirement of secondary surgery or multiple surgeries, and the difficulty in eradicating infections caused by methicillin‐resistant Staphylococcus aureus (MRSA). Hence, smart biodegradable biomaterials that provide effective and precise local anti‐infection effects and can promote the repair of bone defects are actively being developed. Here, a novel nano‐micro composite is fabricated by combining calcium phosphate (CaP) nanosheets with drug‐loaded GelMA microspheres via microfluidic technology. The microspheres are covalently linked with vancomycin (Van) through an oligonucleotide (oligo) linker using an EDC/NHS carboxyl activator. Accordingly, a smart nano‐micro composite called “CaP@MS‐Oligo‐Van” is synthesized. The porous CaP@MS‐Oligo‐Van composites can target and capture bacteria. They can also release Van in response to the presence of bacterial micrococcal nuclease and Ca2+, exerting additional antibacterial effects and inhibiting the inflammatory response. Finally, the released CaP nanosheets can promote bone tissue repair. Overall, the findings show that a rapid, targeted drug release system based on CaP@MS‐Oligo‐Van can effectively target bone tissue infections. Hence, this agent holds potential in the clinical treatment of osteomyelitis caused by MRSA.

show abstract

Section: Introductionmentioning

confidence: 99%